廣州白雲山医药集团股份有限公司
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.
(a joint stock company with limited liability established in the People's Republic of China)
(H Share Stock Code: 00874)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

Reference is made to the annual report of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the "**Company**") for the year ended 31 December 2025 (the "**Annual Report**"). The Annual Report was published by the Company on 22 April 2026. Unless otherwise defined herein, capitalised terms used herein shall have the same meanings as defined in the Annual Report.

In addition to the information disclosed in the Annual Report, the Company hereby provides further information as follows:

With respect to the disclosure of related party transactions, the Company hereby confirms that it has complied with the requirements in Chapter 14A of the Listing Rules of HKEX, it has also complied with the disclosure requirements in accordance with Chapter 14A of the Listing Rules of HKEX.

The supplemental information in this announcement does not affect the other information contained in the Annual Report. Save as disclosed in this announcement, all other information contained in the Annual Report remains unchanged.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 10 September 2026

As at the date of this announcement, the Board comprises (i) Mr. Chen Jiehui, Mr. Yuan Cheng, Mr. Cheng Hongjin, Mr. Tang Heping, Ms. Liu Lan and Mr. Liu Hong as executive directors; (ii) Mr. Huang Jiyuan as non-executive director; and (iii) Mr. Wong Lung Tak Patrick, Ms. Sun Baoqing, Mr. Wu Xiangneng and Mr. Yang Yinbao as independent non-executive directors.